Singula Bio Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—5

Registered number: 12792274

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS

CURRENT ASSETS
Debtors	5	58,853		18,054
Cash at bank and in hand		144,179		75,647

		203,032		93,701
Creditors: Amounts Falling Due Within One Year	6	(977,119 )		(559,950 )

NET CURRENT ASSETS (LIABILITIES)			(774,087 )		(466,249 )

TOTAL ASSETS LESS CURRENT LIABILITIES			(774,087 )		(466,249 )

Creditors: Amounts Falling Due After More Than One Year	7		(247,381 )		(247,381 )

NET LIABILITIES			(1,021,468 )		(713,630 )

CAPITAL AND RESERVES
Called up share capital	8		300		300
Share premium account			1,890,273		1,890,273
Profit and Loss Account			(2,912,041 )		(2,604,203 )

SHAREHOLDERS' FUNDS			(1,021,468)		(713,630)

Page 1

Page 2

Singula Bio Ltd

Balance Sheet (continued)

As At 31 August 2025

For the year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

The financial statements were approved by the board of directors on 28 May 2026 and were signed on its behalf by:

Mr J McVeigh

Director

The notes on pages 3 to 5 form part of these financial statements.

1. General Information

Singula Bio Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12792274 . The registered office is 20 Ambleside Drive, Headington, Oxford, OX3 0AG.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Going Concern Disclosure

The directors believe that notwithstanding net current liabilities of £774,087 and net liabilities of £1,021,468, the company's financial statements should be prepared on a going concern basis. Based on forecasts prepared by the directors, the directors consider that the company will have adequate future sources of funding or support from external investors to meet the company's needs for a period of at least 12 months from the date of approval of these financial statements. The financial statements do not include any adjustments that may arise from any significant changes in the assumptions used in preparing the forecasts.

2.3. Research and Development

Expenditure on research and development is written off in the year it is incurred.

2.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment

3 years on a straight line basis

The assets’ residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Repairs and maintenance costs are charged to profit or loss during the period in which they are incurred.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined, which is the higher of its fair value less costs to sell and its value in use. Any impairment loss is recognised immediately as an expense within the profit or loss.

2.5. Financial Instruments

Trade and other debtors / creditors

Trade and other debtors are recognised initially at transaction prices less attributable transaction costs. Trade and other creditors are recognised initially at transaction price plus attributable transaction costs. Subsequent to initial recognition they are measured at amortised cost using the effective interest method, less any impairment losses in the case of trade debtors. If the arrangement constitutes a financing transaction, for example if payment is deferred beyond normal business terms, then it is measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument.

Impairment of financial assets

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found an impairment loss is recognised within profit or loss.

For financial assets that are measured at amortised cost, the impairment loss is measured as the difference between the asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate.

...CONTINUED

Page 3

Page 4

Singula Bio Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 August 2025

2.5. Financial Instruments - continued

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset’s carrying amount and the best estimate of the amount that the company would receive for the asset if it were to be sold at the balance sheet date.

2.6. Taxation

Income tax expense represents the sum of the tax currently payable.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

2.7. Pensions

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions in a separate entity. Once the contributions have been paid the company has no further payment obligations. The contributions are recognised as an expense in profit or loss in the periods during which services are rendered by employees.

2.8. Warrants

Warrants issued by the company, as part of finance charges for a loan taken out, which is also convertible into equity, are treated as a company expense, with a corresponding creditor, when the warrants are issued.

The fair value of the warrants granted is measured using the Black-Scholes model.

3. Average Number of Employees

Average number of employees during the year was as follows: 3 (2024: 4)

4. Tangible Assets

	Computer Equipment
	£
Cost
As at 1 September 2024	4,738
Disposals	(3,588 )

As at 31 August 2025	1,150

Depreciation
As at 1 September 2024	4,738
Disposals	(3,588 )

As at 31 August 2025	1,150

Net Book Value
As at 31 August 2025	-

As at 1 September 2024	-

5. Debtors

	2025	2024
	£	£
Due within one year
Other debtors	58,853	18,054

Page 4

Page 5

Singula Bio Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 August 2025

6. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	58,923	13,578
Other loans	800,000	500,000
Other creditors	118,196	43,272
Taxation and social security	-	3,100

	977,119	559,950

Included within other creditors are outstanding pension contributions of £330 (2024: £621).

Of the other loans, the following amounts are secured by a fixed and floating charge over the assets of the company:

2025 2024

£ £

Other loans 800,000 500,000

7. Creditors: Amounts Falling Due After More Than One Year

	2025	2024
	£	£
Other creditors	247,381	247,381

Included within other creditors are warrants of £247,381 (2024: £247,381).

The company issued a warrant instrument for warrant shares during the year, as part of a convertible loan agreement. The warrant instrument has an expiration date of 13 October 2030, and can be exercised into 18,571 Ordinary shares (or 5% of the Fully Diluted Share Capital if further equity shares have been issued) at an exercise price of £0.001. The directors have used the Black-Scholes model to determine the fair value of the warrant instrument.

The fair value of the warrant instrument has been recognised in the profit and loss account and in creditors on the balance sheet.

Equity settled share based payments charges arising - £0 (2024: £247,381)

8. Share Capital

	2025	2024
	£	£
Allotted, Called up and fully paid	300	300

9. Related Party Transactions

At 31 August 2025, a loan of £1,891 (2024: £1,891) was owed to Singula Bio Ltd by the directors. All balances attract a nil rate of interest and are repayable upon demand.

Page 5